The world’s first vaccine against Alzheimer’s is discovered: Preparations begin for human clinical trials

Scientists at the University of New Mexico have made a groundbreaking step in the fight against Alzheimer’s disease: they have developed the world’s first experimental vaccine that directly targets one of the main causes of this neurodegenerative illness — the “tau” protein.

This new vaccine aims to activate the immune system to produce antibodies against the harmful proteins that accumulate in the brain and contribute to neuron damage, memory loss, and disease progression. Instead of merely alleviating symptoms, as most current treatments do, the vaccine seeks to stop the biological cause of the disease at its root.

During the preclinical phase, the vaccine was tested on genetically modified mice and showed impressive results. Researchers report that it significantly reduced the buildup of tau proteins in the brain, potentially preventing further neural damage. This breakthrough offers hope to millions of people around the world suffering from Alzheimer’s, as well as their families.

Following the success in laboratory and animal testing, the scientific team is preparing to begin the first phase of clinical trials in humans — a key step to verify the vaccine’s safety and effectiveness in the human body.

If everything proceeds as expected, this vaccine could mark the beginning of a new era in the fight against Alzheimer’s — a disease that affects over 55 million people worldwide and, until now, has had no definitive or curative treatment.

This development promises not only prevention but possibly also halting the progression of the disease, potentially transforming the trajectory of Alzheimer’s care in the decades to come.

“KORÇA BOOM”